Equities analysts forecast that Endocyte, Inc. (NASDAQ:ECYT) will report earnings per share of ($0.16) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Endocyte’s earnings. The highest EPS estimate is ($0.15) and the lowest is ($0.16). Endocyte reported earnings per share of ($0.26) during the same quarter last year, which would suggest a positive year over year growth rate of 38.5%. The company is expected to issue its next quarterly earnings report on Friday, March 9th.

According to Zacks, analysts expect that Endocyte will report full year earnings of ($1.24) per share for the current fiscal year, with EPS estimates ranging from ($1.25) to ($1.23). For the next year, analysts expect that the firm will report earnings of ($0.91) per share, with EPS estimates ranging from ($1.02) to ($0.79). Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow Endocyte.

Endocyte (NASDAQ:ECYT) last announced its earnings results on Monday, November 6th. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.35) by ($0.20). Endocyte had a negative net margin of 82,235.72% and a negative return on equity of 38.91%. The business had revenue of $0.03 million during the quarter. During the same period in the previous year, the business posted ($0.21) EPS. The business’s quarterly revenue was up .0% compared to the same quarter last year.

A number of analysts have recently weighed in on ECYT shares. Cowen restated a “hold” rating on shares of Endocyte in a research note on Monday, October 2nd. Zacks Investment Research upgraded Endocyte from a “sell” rating to a “hold” rating in a research report on Thursday, November 9th. Wedbush upgraded Endocyte from a “neutral” rating to an “outperform” rating and lifted their price objective for the stock from $2.00 to $7.00 in a research report on Tuesday, October 3rd. Finally, ValuEngine upgraded Endocyte from a “strong sell” rating to a “sell” rating in a research report on Monday, October 2nd.

Shares of Endocyte (NASDAQ ECYT) traded down $0.11 during trading hours on Friday, hitting $4.09. The stock had a trading volume of 704,426 shares, compared to its average volume of 460,083. Endocyte has a 52 week low of $1.17 and a 52 week high of $6.55. The firm has a market capitalization of $178.82, a price-to-earnings ratio of -3.03 and a beta of 2.20.

In related news, VP Christopher P. Leamon sold 23,231 shares of Endocyte stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $5.04, for a total value of $117,084.24. Following the completion of the sale, the vice president now directly owns 150,579 shares in the company, valued at $758,918.16. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Philip S. Low acquired 5,600 shares of the stock in a transaction that occurred on Monday, November 13th. The stock was purchased at an average price of $4.84 per share, with a total value of $27,104.00. Following the completion of the transaction, the insider now owns 283,005 shares of the company’s stock, valued at $1,369,744.20. The disclosure for this purchase can be found here. Over the last quarter, insiders sold 124,253 shares of company stock valued at $562,591. Corporate insiders own 14.86% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the stock. Dimensional Fund Advisors LP increased its position in Endocyte by 34.1% in the second quarter. Dimensional Fund Advisors LP now owns 98,313 shares of the biopharmaceutical company’s stock worth $147,000 after purchasing an additional 25,003 shares during the period. FMR LLC increased its position in Endocyte by 0.9% in the second quarter. FMR LLC now owns 3,540,203 shares of the biopharmaceutical company’s stock worth $5,310,000 after purchasing an additional 31,168 shares during the period. Finally, Goldman Sachs Group Inc. increased its position in Endocyte by 1,064.3% in the second quarter. Goldman Sachs Group Inc. now owns 430,994 shares of the biopharmaceutical company’s stock worth $646,000 after purchasing an additional 393,975 shares during the period. Hedge funds and other institutional investors own 17.58% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Endocyte, Inc. (ECYT) Expected to Announce Earnings of -$0.16 Per Share” was first posted by Daily Political and is the property of of Daily Political. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark laws. The legal version of this news story can be read at https://www.dailypolitical.com/2018/01/09/endocyte-inc-ecyt-expected-to-announce-earnings-of-0-16-per-share.html.

Endocyte Company Profile

Get a free copy of the Zacks research report on Endocyte (ECYT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Endocyte (NASDAQ:ECYT)

Receive News & Ratings for Endocyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte and related companies with MarketBeat.com's FREE daily email newsletter.